Literature DB >> 17876273

Differential effects of prednisolone and azathioprine on the development of human cytomegalovirus replication post liver transplantation.

Gaia Nebbia1, Frank M Mattes, Caroline A Sabin, Dimitrios Samonakis, Nancy Rolando, Andrew K Burroughs, Vincent C Emery.   

Abstract

BACKGROUND: We sought to investigate the impact of different immunosuppressive regimens on human cytomegalovirus (HCMV) incidence and replication dynamics in a cohort of 256 patients after liver transplantation.
METHODS: A time-updated approach was used to determine the risk of developing HCMV replication (>200 genomes/mL blood) within the first 100 days after liver transplantation according to the immunosuppressive regimen being received at specific time points.
RESULTS: In patients receiving tacrolimus, the addition of prednisolone was associated with a significant increased risk of HCMV replication both at baseline (relative rate of infection [RRI]=4.34; P=0.0001) and in a time-updated analysis (RRI=4.68; P=0.0001). However, the addition of azathioprine substantially reduced the risk of HCMV replication to that observed with tacrolimus alone. As expected donor/recipient HCMV serostatus was also a risk factor for viraemia. Multivariable models showed that the tacrolimus plus prednisolone regimen and donor/recipient serostatus were independent risk factors for HCMV replication. Viral replication dynamics showed that the duration of HCMV viraemia, the peak viral load, and the growth rate of HCMV were greatest in patients receiving tacrolimus plus prednisolone although these differences did not reach statistical significance.
CONCLUSIONS: The combination of prednisolone plus tacrolimus as baseline immunosuppression after liver transplantation is associated with a high risk of HCMV replication. This effect can be negated by the addition of azathioprine.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17876273     DOI: 10.1097/01.tp.0000280555.08651.11

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  5 in total

1.  Human cytomegalovirus and Epstein-Barr virus infection in inflammatory bowel disease: need for mucosal viral load measurement.

Authors:  Rachele Ciccocioppo; Francesca Racca; Stefania Paolucci; Giulia Campanini; Lodovica Pozzi; Elena Betti; Roberta Riboni; Alessandro Vanoli; Fausto Baldanti; Gino Roberto Corazza
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

2.  Human Cytomegalovirus and Epstein-Barr virus specific immunity in patients with ulcerative colitis.

Authors:  Rachele Ciccocioppo; Caterina Mengoli; Elena Betti; Giuditta Comolli; Irene Cassaniti; Antonio Piralla; Peter Kruzliak; Martin Caprnda; Lodovica Pozzi; Gino Roberto Corazza; Antonio Di Sabatino; Fausto Baldanti
Journal:  Clin Exp Med       Date:  2021-03-26       Impact factor: 3.984

3.  Glucocorticosteroids trigger reactivation of human cytomegalovirus from latently infected myeloid cells and increase the risk for HCMV infection in D+R+ liver transplant patients.

Authors:  Ellen Van Damme; Sarah Sauviller; Betty Lau; Bart Kesteleyn; Paul Griffiths; Andrew Burroughs; Vincent Emery; John Sinclair; Marnix Van Loock
Journal:  J Gen Virol       Date:  2014-10-13       Impact factor: 3.891

4.  Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30+ Lymphoma.

Authors:  Jean-Jacques Tudesq; Laure Vincent; Julie Lebrun; Yosr Hicheri; Ludovic Gabellier; Timothé Busetto; Corinne Merle; Nathalie Fegueux; Patrice Ceballos; Philippe Quittet; Robert Navarro; Dominique Hillaire-Buys; Guillaume Cartron
Journal:  Open Forum Infect Dis       Date:  2017-04-05       Impact factor: 3.835

Review 5.  Anti-Cytomegalovirus Therapy: Whether and When to Initiate, Those Are the Questions.

Authors:  Yumi Aoyama; Seiko Sugiyama; Takenobu Yamamoto
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.